Asset
ICOVAMENIB
BIOMEA FUSION INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07254286 | phase1 | completed | 2025-09-11 | 2026-01-14 | Biomea Fusion Inc. | Food Effect Study in Healthy Volunteers |
| NCT06152042 | phase2 | completed | 2023-12-28 | 2025-05-20 | Biomea Fusion Inc. | Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus |
| NCT07502508 | phase2 | recruiting | 2026-04-30 | 2027-06-01 | Biomea Fusion Inc. | Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy |
| NCT07502495 | phase2 | active_not_recruiting | 2026-03-27 | 2027-03-01 | Biomea Fusion Inc. | Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets |
| NCT05731544 | phase1_2 | completed | 2022-08-17 | 2024-11-18 | Biomea Fusion Inc. | Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D) |
FDA applications (0)
This company has no applications containing this asset.